Evaluating the Impact of Prior Assumptions in Bayesian Biostatistics
- 24 March 2010
- journal article
- research article
- Published by Springer Nature in Statistics in Biosciences
- Vol. 2 (1) , 1-17
Abstract
A common concern in Bayesian data analysis is that an inappropriately informative prior may unduly influence posterior inferences. In the context of Bayesian clinical trial design, well chosen priors are important to ensure that posterior-based decision rules have good frequentist properties. However, it is difficult to quantify prior information in all but the most stylized models. This issue may be addressed by quantifying the prior information in terms of a number of hypothetical patients, i.e., a prior effective sample size (ESS). Prior ESS provides a useful tool for understanding the impact of prior assumptions. For example, the prior ESS may be used to guide calibration of prior variances and other hyperprior parameters. In this paper, we discuss such prior sensitivity analyses by using a recently proposed method to compute a prior ESS. We apply this in several typical settings of Bayesian biomedical data analysis and clinical trial design. The data analyses include cross-tabulated counts, multiple correlated diagnostic tests, and ordinal outcomes using a proportional-odds model. The study designs include a phase I trial with late-onset toxicities, a phase II trial that monitors event times, and a phase I/II trial with dose-finding based on efficacy and toxicity.Keywords
This publication has 10 references indexed in Scilit:
- Prior Effective Sample Size in Conditionally Independent Hierarchical ModelsBayesian Analysis, 2012
- The Neuroprotection with Statin Therapy for Acute Recovery Trial (Neustart): An Adaptive Design Phase I Dose-Escalation Study of High-Dose Lovastatin in Acute Ischemic StrokeInternational Journal of Stroke, 2008
- Determining the Effective Sample Size of a Parametric PriorBiometrics, 2008
- Bayesian inferences for receiver operating characteristic curves in the absence of a gold standardJournal of Agricultural, Biological and Environmental Statistics, 2006
- Monitoring event times in early phase clinical trials: some practical issuesClinical Trials, 2005
- Dose‐Finding Based on Efficacy–Toxicity Trade‐OffsBiometrics, 2004
- Applied Bayesian Modelling2003
- Assessing the Homogeneity of Three Odds Ratios: A Case Study in Small-Sample Inference2002
- Sequential Designs for Phase I Clinical Trials with Late‐Onset ToxicitiesBiometrics, 2000
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in CancerBiometrics, 1990